지놈앤컴퍼니

314130KOSDAQ기초 의약물질 제조업

55.9 / 100

Reference Date: 2026-06-10

Financial Score19.5 / 40

News Sentiment20.4 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is low with sound financial health but ROE is below the industry average. Plunged 15.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Genom and Company aims to grow into a fully integrated pharmaceutical company by focusing on innovative drug development, utilizing its GNOCLE™ platform to advance pipeline candidates such as the immunotherapy GENA-104 and microbiome-based treatment GEN-001. The company also diversifies its business through CDMO services and its microbiome cosmetics brand 'UIQ'.

Number of Employees

96people

Average Salary

60.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 27.714.0Point

PBR

2.32Industry Average 1.742.5Point

Higher than industry avg (caution)

ROE

-7.20Industry Average -6.033.5Point

In line with industry avg

Debt Ratio

6.62Industry Average 6.624.0Point

In line with industry avg

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲41.3% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲17.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -23.6% (improving, 3yr)

Detailed News Sentiment

6 totalPositive 6Neutral 0Negative 0Average Sentiment Score 81.7

Positive
지놈앤컴퍼니 "빅파마 겨냥… 조기 기술이전 집중"
지놈앤컴퍼니가 빅파마와의 전임상 협력을 통해 기술이전 전략을 강화함으로써 긍정적인 시장 반응을 이끌어냈다.
Positive
"베스트보다 퍼스트"…지놈앤컴퍼니, 신규 타깃 ADC 기술이전 시동
지놈앤컴퍼니가 신규 항체-세포독성제(ADC) 기술의 글로벌 시장 진출을 통해 긍정적인 성과를 이어가고 있다.
Positive
지놈앤컴퍼니, BIO USA서 ADC 파이프라인 글로벌 파트너링 본격화
지놈앤컴퍼니가 주요 바이오 컨퍼런스에서 글로벌 파트너십 확대를 통해 신약 개발 기회를 확대하고 있다.

Detailed Momentum

52-week position5.0Point

52w mid range (46%)

Current 5,950Won52-week high 9,97052-week low 2,465

1-month return0.0Point

1m -15.60% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

17 totalPositive 0Neutral 17Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-29
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-29
Neutral주식등의대량보유상황보고서(일반)2026-05-29
Neutral주식등의대량보유상황보고서(약식)2026-05-27
Neutral주식등의대량보유상황보고서(약식)2026-05-27